Canagliflozin vs Epithalon
A side-by-side research comparison of Canagliflozin and Epithalon across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Canagliflozin | Epithalon |
|---|---|---|
| Full name | Canagliflozin (SGLT2 Inhibitor) | Epithalon (Epitalon / Epithalone) |
| Category | Anti-Aging | Anti-Aging |
| Status | FDA-approved drug | Research compound |
| Mechanism | Blocks the sodium-glucose cotransporter 2 in the kidney, causing excess glucose to be excreted in urine. This lowers blood glucose independent of insulin, reduces blood pressure and weight, and produces cardio-renal protective effects. | Activates telomerase reverse transcriptase (hTERT) expression for telomere maintenance. Also normalizes circadian rhythm via melatonin regulation and modulates antioxidant enzymes. |
| Molecular weight | 444.52 Da | 390.4 Da |
| Half-life | ~11-13 hours | 3-4 hours |
| Bioavailability | ~65% oral | High (SubQ) |
| Typical dose | 100-300 mg per day | 5-10 mg |
| Frequency | Once daily | Daily for 10-20 days |
| Route | Oral tablet | Subcutaneous injection |
Canagliflozin reported benefits
- Insulin-independent glucose lowering
- Cardiovascular protection
- Kidney protection
- Blood pressure reduction
- Weight loss
- Longevity signal (ITP data)
Epithalon reported benefits
- Telomerase activation
- Telomere lengthening
- Melatonin normalization
- Improved sleep patterns
- Antioxidant enzyme upregulation
- Potential lifespan extension
Related comparisons
Research and educational reference only. Not medical advice.